Search

Your search keyword '"Chekerov R"' showing total 233 results
Start Over Author "Chekerov R"
233 results on '"Chekerov R"'

1. INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line

Author

Colombo, N., Gadducci, A., Sehouli, J., Rulli, E., Mäenpää, J., Sessa, C., Montes, A., Ottevanger, N. B., Berger, R., Vergote, I., D’Incalci, M., Churruca Galaz, C., Chekerov, R., Nyvang, G. B., Riniker, S., Herbertson, R., Fossati, R., Barretina-Ginesta, M. P., Deryal, M., Mirza, M. R., Biagioli, E., Iglesias, M., Funari, G., Romeo, M., Tasca, G., Pardo, B., Tognon, G., Rubio-Pérez, M. J., DeCensi, A., De Giorgi, U., Zola, P., Benedetti Panici, P., Aglietta, M., Arcangeli, V., Zamagni, C., Bologna, A., Westermann, A., Heinzelmann-Schwarz, V., Tsibulak, I., Wimberger, P., and Poveda, A.

Published
2023
Full Text
View/download PDF

6. Influence of migrant background on patient preference and expectations in breast and gynecological malignancies (NOGGO-expression V study): results of a prospective multicentre study in 606 patients in Germany

Author

Dimitrova, D., Naghavi, B., Richter, R., Nasser, S., Chekerov, R., Braicu, E. I., David, M., Blohmer, J., Inci, G., Torsten, U., Oskay-Özcelik, G., Blau, I., Fersis, N., Holzgreve, A., Keil, E., Keller, M., Keilholz, U., and Sehouli, J.

Published
2021
Full Text
View/download PDF

8. Expression III: patients’ expectations and preferences regarding physician–patient relationship and clinical management—results of the international NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries

Author

Oskay-Özcelik, G., Alavi, S., Richter, R., Keller, M., Chekerov, R., Cecere, S.C., Cormio, G., Joly, F., Kurtz, J.E., du Bois, A., Maciejewski, M., Jedryka, M., Vergote, I., Van Nieuwenhuysen, E., Casado, A., Mendiola, C., Achimas-Cadariu, P., Vlad, C., Reimer, D., Zeimet, A.G., Friedlander, M., and Sehouli, J.

Published
2018
Full Text
View/download PDF

9. INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line

Author

INOVATYON study group, Colombo, N., Gadducci, A., Sehouli, J., Rulli, E., Mäenpää, J., Sessa, C., Montes, A., Ottevanger, N. B., Berger, R., Vergote, I., D'Incalci, M., Churruca Galaz, C., Chekerov, R., Nyvang, G. B., Riniker, S., Herbertson, R., Fossati, R., Barretina-Ginesta, M. P., Deryal, M., Mirza, M. R., Biagioli, E., Iglesias, M., Funari, G., Romeo, M., Tasca, G., Pardo, B., Tognon, G., Rubio-Pérez, M. J., DeCensi, A., De Giorgi, U., Zola, P., Benedetti Panici, P., Aglietta, M., Arcangeli, V., Zamagni, C., Bologna, A., Westermann, A., Heinzelmann-Schwarz, V., Tsibulak, I., Wimberger, P., Poveda, A., Tampere University, Clinical Medicine, Department of Gynaecology and Obstetrics, Colombo, N, Gadducci, A, Sehouli, J, Rulli, E, Mäenpää, J, Sessa, C, Montes, A, Ottevanger, N, Berger, R, Vergote, I, D'Incalci, M, Churruca Galaz, C, Chekerov, R, Nyvang, G, Riniker, S, Herbertson, R, Fossati, R, Barretina-Ginesta, M, Deryal, M, Mirza, M, Biagioli, E, Iglesias, M, Funari, G, Romeo, M, Tasca, G, Pardo, B, Tognon, G, Rubio-Pérez, M, Decensi, A, De Giorgi, U, Zola, P, Benedetti Panici, P, Aglietta, M, Arcangeli, V, Zamagni, C, Bologna, A, Westermann, A, Heinzelmann-Schwarz, V, Tsibulak, I, Wimberger, P, and Poveda, A

Subjects
Cancer Research, All institutes and research themes of the Radboud University Medical Center, Oncology, 3123 Gynaecology and paediatrics, 3122 Cancers, platinum-free interval, Women's cancers Radboud Institute for Health Sciences [Radboudumc 17]
Abstract

Background This trial investigated the hypothesis that the treatment with trabectedin/PLD (TP) to extend the platinum-free interval (TFIp) can improve overall survival (OS) in patients with recurrent ovarian cancer (OC). Methods Patients with OC (up to two previous platinum-based lines), with a TFIp of 6–12 months, were randomised to receive carboplatin/PLD (CP) or TP followed by platinum therapy at relapse. The primary endpoint was OS (HR: 0.75). Results The study enrolled 617 patients. The median TFIp was 8.3 months and 30.3% of patients had received two previous platinum lines. 74% and 73.9% of patients, respectively, received a subsequent therapy (ST) in the CP and TP arm; in the latter TP arm 87.2% of ST was platinum-based, as per protocol. The median OS was 21.4 for CP and 21.9 months for TP (HR 1.13; 95% CI: 0.94–1.35; p = 0.197). Grade 3–5 adverse reactions occurred in 37.1% of patients in the CP arm and 69.7% of patients in the TP arm, and the most frequent were neutropenia (22.8% CP, 39.5% TP), gastrointestinal (7.1% CP, 17.4% TP), hepatic (0.7% CP, 19.1% TP). Conclusions This study did not meet the primary endpoint. CP combination remains the standard for patients with recurrent OC and a 6–12 months TFIp; TP is an effective treatment in patients suffering from persistent platinum toxicities. Clinical trial registration ClinicalTrials.gov, number NCT01379989.

Published
2023

10. INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line

Author

Colombo, N, Gadducci, A, Sehouli, J, Rulli, E, Mäenpää, J, Sessa, C, Montes, A, Ottevanger, N, Berger, R, Vergote, I, D'Incalci, M, Churruca Galaz, C, Chekerov, R, Nyvang, G, Riniker, S, Herbertson, R, Fossati, R, Barretina-Ginesta, M, Deryal, M, Mirza, M, Biagioli, E, Iglesias, M, Funari, G, Romeo, M, Tasca, G, Pardo, B, Tognon, G, Rubio-Pérez, M, Decensi, A, De Giorgi, U, Zola, P, Benedetti Panici, P, Aglietta, M, Arcangeli, V, Zamagni, C, Bologna, A, Westermann, A, Heinzelmann-Schwarz, V, Tsibulak, I, Wimberger, P, Poveda, A, Ottevanger, N B, Nyvang, G B, Barretina-Ginesta, M P, Mirza, M R, Rubio-Pérez, M J, DeCensi, A, Colombo, N, Gadducci, A, Sehouli, J, Rulli, E, Mäenpää, J, Sessa, C, Montes, A, Ottevanger, N, Berger, R, Vergote, I, D'Incalci, M, Churruca Galaz, C, Chekerov, R, Nyvang, G, Riniker, S, Herbertson, R, Fossati, R, Barretina-Ginesta, M, Deryal, M, Mirza, M, Biagioli, E, Iglesias, M, Funari, G, Romeo, M, Tasca, G, Pardo, B, Tognon, G, Rubio-Pérez, M, Decensi, A, De Giorgi, U, Zola, P, Benedetti Panici, P, Aglietta, M, Arcangeli, V, Zamagni, C, Bologna, A, Westermann, A, Heinzelmann-Schwarz, V, Tsibulak, I, Wimberger, P, Poveda, A, Ottevanger, N B, Nyvang, G B, Barretina-Ginesta, M P, Mirza, M R, Rubio-Pérez, M J, and DeCensi, A

Abstract

BACKGROUND: This trial investigated the hypothesis that the treatment with trabectedin/PLD (TP) to extend the platinum-free interval (TFIp) can improve overall survival (OS) in patients with recurrent ovarian cancer (OC). METHODS: Patients with OC (up to two previous platinum-based lines), with a TFIp of 6-12 months, were randomised to receive carboplatin/PLD (CP) or TP followed by platinum therapy at relapse. The primary endpoint was OS (HR: 0.75). RESULTS: The study enrolled 617 patients. The median TFIp was 8.3 months and 30.3% of patients had received two previous platinum lines. 74% and 73.9% of patients, respectively, received a subsequent therapy (ST) in the CP and TP arm; in the latter TP arm 87.2% of ST was platinum-based, as per protocol. The median OS was 21.4 for CP and 21.9 months for TP (HR 1.13; 95% CI: 0.94-1.35; p = 0.197). Grade 3-5 adverse reactions occurred in 37.1% of patients in the CP arm and 69.7% of patients in the TP arm, and the most frequent were neutropenia (22.8% CP, 39.5% TP), gastrointestinal (7.1% CP, 17.4% TP), hepatic (0.7% CP, 19.1% TP). CONCLUSIONS: This study did not meet the primary endpoint. CP combination remains the standard for patients with recurrent OC and a 6-12 months TFIp; TP is an effective treatment in patients suffering from persistent platinum toxicities. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, number NCT01379989.

Published
2023

11. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR)

Author

Sehouli, J., Chekerov, R., Reinthaller, A., Richter, R., Gonzalez-Martin, A., Harter, P., Woopen, H., Petru, E., Hanker, L.C., Keil, E., Wimberger, P., Klare, P., Kurzeder, C., Hilpert, F., Belau, A.K., Zeimet, A., Bover-Barcelo, I., Canzler, U., Mahner, S., and Meier, W.

Published
2016
Full Text
View/download PDF

20. Role of serum concentration of VEGFR1 and TIMP2 on clinical outcome in primary cervical cancer: Results of a companion protocol of the randomized, NOGGO–AGO phase III adjuvant trial of simultaneous cisplatin-based radiochemotherapy vs. carboplatin and paclitaxel containing sequential radiotherapy

Author

Braicu, E.I., Fotopoulou, C., Chekerov, R., Richter, R., Blohmer, J., Kümmel, S., Stamatian, F., Yalcinkaya, I., Mentze, M., Lichtenegger, W., and Sehouli, J.

Published
2013
Full Text
View/download PDF

22. Surgery due to mechanical bowel obstruction in relapsed ovarian cancer: clinical and surgical results of a bicentric analysis of 87 patients (Oct, 10.1007/s00404-021-06237-x, 2021)

Author

Armbrust, R, Chekerov, R, Sander, S, Biebl, M, Chopra, S, Krell, J, Rinne, N, Nixon, K, Fotopoulou, C, Sehouli, J, and Ovarian Cancer Action

Subjects
Science & Technology, Obstetrics & Gynecology, 1114 Paediatrics and Reproductive Medicine, Obstetrics & Reproductive Medicine, Life Sciences & Biomedicine
Published
2021

26. 624 NOGGO Ov-42/MAMOC: rucaparib MAintenance after bevacizumab maintenance following carboplatin based first line chemotherapy in OvCA patients

Author

Braicu, E, primary, Wimberger, P, additional, Relógio, A, additional, Dysarz, J, additional, Gerber, J, additional, Eichbaum, M, additional, Deryal, M, additional, Chekerov, R, additional, Grabowksi, J, additional, Rose, M, additional, Endres, M, additional, Scheibenbogen, C, additional, Woopen, H, additional, and Sehouli, J, additional

Published
2021
Full Text
View/download PDF

28. 184 UPLIFT (ENGOT-ov67/GOG-3048) a pivotal cohort of upifitamab rilsodotin, a NaPi2b-directed ADC in platinum-resistant ovarian cancer

Author

Concin, N, primary, Hamilton, E, additional, Randall, LM, additional, Banerjee, S, additional, Mileshkin, L, additional, Coleman, RL, additional, Monk, B, additional, Mirza, MR, additional, Savarese, A, additional, Ray-Coquard, I, additional, Perez Fidalgo, JA, additional, Bernardo, P, additional, Putiri, E, additional, Burger, R, additional, Mosher, R, additional, Richardson, D, additional, Cibula, D, additional, Madry, R, additional, Chekerov, R, additional, and Van Gorp, T, additional

Published
2021
Full Text
View/download PDF

30. 1056 Live surgical broadcast and patient outcome – 10 years of experience from the international Charité MAYO conferences 2010–2019

Author

Altmann, J, primary, Chekerov, R, additional, Fotopoulou, C, additional, Du Bois, A, additional, Cliby, W, additional, Dowdy, SC, additional, Podratz, K, additional, Lichtenegger, W, additional, Camara, O, additional, Tunn, R, additional, Cibula, D, additional, Kümmel, S, additional, Vergote, IB, additional, Chopra, S, additional, Biebl, M, additional, Chiantera, V, additional, Neymeyer, J, additional, Muallem, Z, additional, Blohmer, JU, additional, and Sehouli, J, additional

Published
2021
Full Text
View/download PDF

32. 764P Survey on the practical implementation of BRCA gene and HRD-testing and PARP-inhibitor management in Germany: A national NOGGO/JAGO-AGO intergroup study

Author

Baum, J., primary, Nguyen, B.D., additional, Meyer-Wilmes, P., additional, Kreklau, A., additional, Buschmann, C., additional, Boz, S., additional, Fotopoulou, C., additional, Chekerov, R., additional, Braicu, E.I., additional, Hummel, M., additional, Sehouli, J., additional, and Pietzner, K., additional

Published
2021
Full Text
View/download PDF

33. Additional file 1 of Influence of migrant background on patient preference and expectations in breast and gynecological malignancies (NOGGO-expression V study): results of a prospective multicentre study in 606 patients in Germany

Author

Dimitrova, D., Naghavi, B., Richter, R., Nasser, S., Chekerov, R., Braicu, E. I., David, M., Blohmer, J., Inci, G., Torsten, U., Oskay-Özcelik, G., Blau, I., Fersis, N., Holzgreve, A., Keil, E., Keller, M., Keilholz, U., and Sehouli, J.

Abstract

Additional file 1: Supplemental Table 1. Distribution of study participants according to the way of recruitment. Supplemental Table 2. Factors predicting the possibility for not being offered or not participating in a clinical trial.

Published
2021
Full Text
View/download PDF

37. INOVATYON study: Randomized phase III international study comparing trabectedin/PLD followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line

Author

Colombo, N., Gadducci, A., Sehouli, J., Biagioli, E., Nyvang, G-B., Riniker, S., Montes, A., Ottevanger, N., Zeimet, A. G. G., Vergote, I. B., Funari, G., Baldoni, A., Tognon, G., De Censi, A., Churruca Galaz, C., Chekerov, R., Maenpaa, J., Rulli, E., Fossati, R., and Poveda, A.

Published
2020
Full Text
View/download PDF

40. Fertility-preserving treatment of stage IA, well-differentiated endometrial carcinoma (EC) or atypical complex hyperplasia (ACH) in young women with hysteroscopic resection and high-dose progesterone therapy

Author

Pasternak, J, additional, Obermayr, M, additional, Schepelmann, J, additional, Sternberg, J, additional, Czogalla, B, additional, Burges, A, additional, Hennings, A, additional, Wallwiener, M, additional, Kommoss, S, additional, Brucker, S.Y, additional, Wölber, L, additional, Boschetti, E, additional, Chekerov, R, additional, Pietzner, K, additional, and Sehouli, J, additional

Published
2020
Full Text
View/download PDF

41. LBA30 INOVATYON study: Randomized phase III international study comparing trabectedin/PLD followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line

Author

Colombo, N., primary, Gadducci, A., additional, Sehouli, J., additional, Biagioli, E., additional, Nyvang, G-B., additional, Riniker, S., additional, Montes, A., additional, Ottevanger, N., additional, Zeimet, A.G.G., additional, Vergote, I.B., additional, Funari, G., additional, Baldoni, A., additional, Tognon, G., additional, De Censi, A., additional, Galaz, C. Churruca, additional, Chekerov, R., additional, Maenpaa, J., additional, Rulli, E., additional, Fossati, R., additional, and Poveda, A., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results